World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
75
Citations
41246
World Ranking
18962
National Ranking
107

Overview

Werner Scheithauer was affiliated with the Medical University of Vienna in Austria. Their research focused primarily on the field of Medicine, with a significant emphasis on Oncology. The scientist contributed extensively to academic literature, authoring 54 publications in the main field of Medicine.

Their work spanned several subfields, notably:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Hepatology
  • Cancer Research
  • Pathology and Forensic Medicine

The main research topics covered in their publications included:

  • Colorectal Cancer Treatments and Studies
  • Gastric Cancer Management and Outcomes
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Lung Cancer Treatments and Mutations
  • Cancer Genomics and Diagnostics
  • Cancer Treatment and Pharmacology
  • Genetic factors in colorectal cancer

Werner Scheithauer co-authored frequently with several researchers, among whom the most notable were:

  • Sebastian Stintzing (14 publications)
  • Thomas Decker (13 publications)
  • Alexander Kiani (13 publications)
  • Christoph Kahl (13 publications)
  • Dominik Paul Modest (13 publications)

Their research appeared in various respected scientific journals, with recurring publications in:

  • Journal of Clinical Oncology (6 publications)
  • European Journal of Cancer (3 publications)
  • Annals of Oncology (3 publications)
  • British Journal of Cancer (2 publications)
  • Journal of Clinical Medicine (1 publication)

Selected recent papers by Werner Scheithauer included:

  • Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study (2023, Journal of Clinical Oncology)
  • FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial (2020, British Journal of Cancer)
  • Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients (2020, Journal of Clinical Medicine)
  • Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer (2020, Thrombosis Research)
  • Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group (2020, Annals of Oncology)

Best Publications

  • Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

    Leonard B. Saltz;Stephen Clarke;Eduardo Díaz-Rubio;Werner Scheithauer

  • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    E. Van Cutsem;A. Cervantes;R. Adam;A. Sobrero

  • Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

    Bernard Nordlinger;Halfdan Sorbye;Bengt Glimelius;Bengt Glimelius;Graeme J Poston

  • FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

    Volker Heinemann;Ludwig Fischer von Weikersthal;Thomas Decker;Alexander Kiani

  • ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

    H J Schmoll;E Van Cutsem;A Stein;V Valentini

  • Capecitabine as Adjuvant Treatment for Stage III Colon Cancer

    Chris Twelves;Alfred Wong;Marek P. Nowacki;Markus Abt

  • Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983) : long-term results of a randomised, controlled, phase 3 trial

    Bernard Nordlinger;Halfdan Sorbye;Bengt Glimelius;Graeme J Poston

  • EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

    Alberto F. Sobrero;Joan Maurel;Louis Fehrenbacher;Werner Scheithauer

  • Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

    Jim Cassidy;Stephen Clarke;Eduardo Díaz-Rubio;Werner Scheithauer

  • Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

    David Cunningham;Ian Chau;Deborah D. Stocken;Juan W. Valle

  • Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

    Richard Herrmann;György Bodoky;Thomas Ruhstaller;Bengt Glimelius

  • Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

    Eric Van Cutsem;Walter L. Vervenne;Jaafar Bennouna;Yves Humblet

  • Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study

    Thierry André;Armand De Gramont;Dewi Vernerey;Benoist Chibaudel

  • nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

    David Goldstein;Robert Hassan El-Maraghi;Pascal Hammel;Volker Heinemann

  • Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients

    CH Kohne;D Cunningham;F Di Costanzo;B Glimelius

  • Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer

    Brigit Gruenberger;Dietmar Tamandl;Johannes Schueller;Werner Scheithauer

  • FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.

    Sebastian Stintzing;Sebastian Stintzing;Dominik P Modest;Dominik P Modest;Lisa Rossius;Markus M Lerch

  • Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors

    I Virgolini;M Raderer;A Kurtaran;P Angelberger

  • Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial

    W. Scheithauer;J. McKendrick;S. Begbie;M. Borner

  • Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983)

    Bernard Nordlinger;Halfdan Sorbye;Bengt Glimelius;Graeme J Poston

Frequent Co-Authors

Volker Heinemann
Volker Heinemann Ludwig-Maximilians-Universität München
Andreas Jung
Andreas Jung University of Zurich
Markus Raderer
Markus Raderer Medical University of Vienna
Thomas Decker
Thomas Decker University of Vienna
Christoph C. Zielinski
Christoph C. Zielinski Medical University of Vienna
Bengt Glimelius
Bengt Glimelius Uppsala University
Aimery de Gramont
Aimery de Gramont Grenoble Alpes University
Thierry André
Thierry André Université Paris Cité
Burghardt Wittig
Burghardt Wittig Freie Universität Berlin

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine isn’t limited to becoming a physician. There are numerous online degree options that can launch or advance your healthcare journey while offering flexibility and affordability.

Entry-level positions in the medical field, such as medical billing and coding, are in high demand. If you’re interested in joining the healthcare sector quickly or at a lower cost, consider enrolling in a low cost medical coding and billing online program. These programs equip you with essential skills to manage healthcare records and insurance claims.

For those aspiring to become registered nurses or advance their nursing careers, there are cheapest online nursing programs and affordable np programs available online. Nurse practitioner programs, in particular, prepare you for advanced clinical roles and increased responsibility.

Ambitious nursing professionals can further their expertise with online nursing phd programs. A PhD opens doors to leadership, research, and teaching positions in the healthcare industry.

Best Scientists Citing Werner Scheithauer

Recently Published Articles